AAP News TODAY 2016 - Sunday, October 23, 2016 - 20
Current quadrivalent meningococcal vaccines only
protect against 4 (A, C, W-135, Y) of the 5 main
serogroups, but not serogroup B, an aggressive,
potentially deadly strain that accounted for 33% of
meningococcal disease cases among subjects <1 to
≥65 years of age in the US in 2013 (n=52*).1,2
Meningococcal disease can cause excessive skin
scarring, brain damage, hearing loss, amputation, or
even death within 24 hours of symptom onset.3,4
Between 110 and 188 cases of meningococcal group B
disease occurred annually in patients <1 to ≥65 years of
age in the US between 2008 and 2012 (0.04-0.06/100,000
population).5 Up to 1 in 5 survivors of meningococcal
disease will suffer from sequelae.4
BEXSERO can help close the protection gap, with
2 doses administered at least 1 month apart, to help
protect against meningococcal group B disease.6
Consider BEXSERO to help protect your 10- to 25-year-old
patients against meningococcal group B disease.
Vaccination with BEXSERO may not provide protection
against all meningococcal serogroup B strains.
*Represents total meningococcal cases per 100,000
US population (excluding Oregon).
BEXSERO is a vaccine indicated for active immunization
to prevent invasive disease caused by Neisseria
meningitidis serogroup B. BEXSERO is approved for use
in individuals 10 through 25 years of age.
IMPORTANT SAFETY INFORMATION FOR BEXSERO
* BEXSERO is contraindicated in cases of hypersensitivity,
including severe allergic reaction, to any component of the
vaccine, or after a previous dose of BEXSERO
* The most common solicited adverse reactions observed in
clinical trials were pain at the injection site (≥83%), myalgia
(≥48%), erythema (≥45%), fatigue (≥35%), headache (≥33%),
induration (≥28%), nausea (≥18%), and arthralgia (≥13%)
* Appropriate observation and medical treatment should always
be readily available in case of an anaphylactic event following
the administration of the vaccine
* Vaccination with BEXSERO may not provide protection against
all meningococcal serogroup B strains
* The tip caps of the prefilled syringes contain natural rubber latex,
which may cause allergic reactions in latex-sensitive individuals
* Vaccination with BEXSERO may not result in protection in all
* Syncope (fainting) can occur in association with administration
of BEXSERO. Ensure procedures are in place to avoid injury from
falling associated with syncope
Please see brief summary of full Prescribing Information on following pages.
References: 1. Centers for Disease Control and Prevention. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices
(ACIP). MMWR. 2013;62(RR-2):1-32. 2. Centers for Disease Control and Prevention. Active bacterial core surveillance report, emerging infections program network, Neisseria meningitidis,
2013. www.cdc.gov/abcs/reports-findings/survreports/mening13.pdf. Accessed May 4, 2015. 3. Centers for Disease Control and Prevention. Preteens, teens need meningococcal vaccine.
www.cdc.gov/features/meningococcal. Accessed May 21, 2015. 4. MacNeil J, Cohn A. Meningococcal disease. In: Roush SW, Baldy LM, eds. Manual for the Surveillance of VaccinePreventable Diseases. Atlanta, GA: Centers for Disease Control and Prevention; 2011. http://www.cdc.gov/vaccines/pubs/surv-manual/chpt08-mening.pdf. Accessed May 4, 2015.
5. Centers for Disease Control and Prevention. Summary of notifiable diseases-United States, 2012. MMWR. 2014;61(53):1-124. 6. Prescribing Information for BEXSERO.
BEXSERO is a registered trademark of the GSK group of companies.
©2015 GSK group of companies.
All rights reserved. Printed in USA. 465406R0 August 2015
Please visit us at the GSK
booth for more information.
Approval of BEXSERO is based on demonstration of
immune response, as measured by serum bactericidal
activity against three serogroup B strains representative
of prevalent strains in the United States. The effectiveness
of BEXSERO against diverse serogroup B strains has not